NDRM NeuroDerm Ltd. - Ordinary Share

30.40
+0.85  (3%)
Previous Close 29.55
Open 29.75
Price To book 5.57
Market Cap 800.68M
Shares 26,338,000
Volume 233,577
Short Ratio 4.69
Av. Daily Volume 234,473

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial met key primary and secondary endpoints - March 1, 2017.
ND0612H (Trial 006)
Severe Parkinson's Disease
Phase 3 trial suspended, to be replaced by two PK trials due to be initiated 2H 2017.
ND0612L
Parkinson's Disease

Latest News

  1. NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson’s Disease and Movement Disorders
  2. European Medicines Agency Accepts Design of NeuroDerm’s ND0612 Phase III iNDiGO Efficacy Trial
  3. NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders
  4. Today's Research Reports on Stocks to Watch: NeuroDerm and Exact Sciences
  5. NeuroDerm CEO to Present at the Jefferies Global Healthcare Conference on June 7, 2017
  6. NeuroDerm ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders
  7. NeuroDerm Announces First Quarter 2017 Financial Results
  8. NeuroDerm Ltd. (Nasdaq: NDRM) to Ring The Nasdaq Stock Market Opening Bell
  9. NeuroDerm to Ring the Nasdaq Stock Market Opening Bell and Participate in the Parkinson’s Unity Walk
  10. Post Earnings Coverage as NeuroDerm Reported FY16 Results
  11. NeuroDerm to Host Investor Day on April 21, 2017
  12. NeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results
  13. After Valeant, Here are 5 Drug Stocks Bill Ackman Should Buy Instead
  14. Can The Uptrend Continue for NeuroDerm (NDRM)?
  15. Neuroderm Hits 52-week High on Positive Results (NDRM)
  16. Here's Why Neuroderm Ltd Stock Is Surging Today